Is creatine kinase a valid aid in early cardiac muscle damage detection during treatment for childhood acute lymphoblastic leukemia? A case report - Report - MDSpire
Advertisement
Is creatine kinase a valid aid in early cardiac muscle damage detection during treatment for childhood acute lymphoblastic leukemia? A case report
Clinical Report: Evaluating the Role of Creatine Kinase in Cardiac Injury Detection
Overview
This report discusses a pediatric case of acute lymphoblastic leukemia (ALL) where elevated creatine kinase (CK) levels were detected during chemotherapy. It explores the potential of CK as a biomarker for early identification of cardiac muscle injury in this patient population.
Background
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with a high survival rate but significant late complications, including cardiotoxicity from chemotherapy. Monitoring cardiac health during treatment is crucial, as survivors face increased cardiovascular risks. Identifying reliable biomarkers for cardiac injury can enhance patient management and outcomes.
Data Highlights
No numerical data or trial data provided in the article.
Key Findings
CK levels can rise significantly during chemotherapy in pediatric ALL patients.
Elevated CK levels may indicate cardiac muscle injury, even in asymptomatic patients.
Current guidelines favor high-sensitivity cardiac troponin (hs-cTn) over CK for myocardial injury detection.
CK is prone to false positives due to skeletal muscle injury, complicating its use as a cardiac biomarker.
Monitoring cardiac health is essential due to the risk of late cardiotoxicity in ALL survivors.
Clinical Implications
Clinicians should be cautious in interpreting elevated CK levels during chemotherapy, as they may not reliably indicate cardiac injury. Emphasis should be placed on using hs-cTn and other biomarkers for accurate cardiac monitoring in pediatric cancer patients.
Conclusion
The case highlights the need for careful evaluation of CK as a biomarker for cardiac injury in pediatric ALL patients, advocating for the use of more reliable markers like hs-cTn in clinical practice.
by Grazia Fazio, Jari Intra, Orsola Montini, Laura Rachele Bettini, Giacomo Gotti, Alessandra Sala, Silvia Bungaro, Giovanni Cazzaniga, Carmelo Rizzari, Adriana Balduzzi, Marco Casati